Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neurodegenerative, renal, and cardiovascular diseases.

Related Keywords

Mehmet Gundogdu ,Niyati Gupta Kheskani ,Helen Walden ,University Of Glasgow Uo ,University Of Glasgow ,Ubiquigent Limited ,Head Of School Molecular Biosciences ,Professor Helen Walden ,Principal Scientist ,Structural Biology ,Molecular Biosciences ,Professor Walden ,Sheelagh Frame ,Chief Scientific Officer ,Drug Discovery ,Iochemistry ,Crystallography ,N Vitro ,Protein ,Research ,Research Project ,Herapeutics ,